Page last updated: 2024-10-24
spermatoproteasome complex
Definition
Target type: cellularcomponent
A proteasome specifically found in mammalian testis. Contains the proteasome activator PA200 in the regulatory particle, and beta1i, beta2i, beta5i and/or alpha4s in the core (20S) subunit. Beta1i, beta2i and beta5i are inducible catalytic subunits, closely related to beta1, beta2 and beta5. Alpha4s is a sperm-specific 20S subunit, but unlike other alternative 20S subunits alpha4s lies in the outer alpha-ring and lacks catalytic activity. [GOC:sp, PMID:23706739]
Proteins (4)
| Protein | Definition | Taxonomy |
|---|---|---|
| Proteasome subunit alpha-type 8 | A proteasome subunit alpha-type 8 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8TAA3] | Homo sapiens (human) |
| Proteasome subunit beta type-10 | A proteasome subunit beta type-10 that is encoded in the genome of human. [PRO:DNx] | Homo sapiens (human) |
| Proteasome subunit beta type-9 | A proteasome subunit beta type-9 that is encoded in the genome of human. [PRO:DNx] | Homo sapiens (human) |
| Proteasome subunit beta type-8 | A proteasome subunit beta type-8 that is encoded in the genome of human. [PRO:DNx] | Homo sapiens (human) |
Compounds (22)
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| chlorpromazine | chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety. Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | organochlorine compound; phenothiazines; tertiary amine | anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug |
| bortezomib | amino acid amide; L-phenylalanine derivative; pyrazines | antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor | |
| sdz 283-910 | SDZ 283-910: structure in first source | ||
| benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative. | amino aldehyde; carbamate ester; tripeptide | proteasome inhibitor |
| captax | 1,3-benzothiazole-2-thiol : 1,3-Benzothiazole substituted at the 2-position with a sulfanyl group. captax: RN given refers to parent cpd | aryl thiol; benzothiazoles | carcinogenic agent; metabolite |
| 2-mercaptobenzimidazole | 2-mercaptobenzimidazole: purine synthesis antimetabolite; RN given refers to parent cpd | ||
| 2-mercaptobenzoxazole | benzoxazole | ||
| 5-chloro-1h-benzimidazole-2-thiol | 5-chloro-1H-benzimidazole-2-thiol: trypanocidal | ||
| 5-chloro-2-mercaptobenzothiazole | |||
| benzyloxycarbonyl-phe-ala-fluormethylketone | cathepsin B inhibitor : A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1). | ||
| am 404 | anilide | ||
| lactacystin | lactam; S-substituted L-cysteine | ||
| clasto-lactacystin beta-lactone | clasto-lactacystin beta-lactone: active metabolite of lactacystin; inhibits 20 S proteasome; structure in first source | ||
| marizomib | marizomib: a proteasome inhibitor from a marine bacterium Salinospora; structure in first source | beta-lactone; gamma-lactam; organic heterobicyclic compound; organochlorine compound; salinosporamide | antineoplastic agent; proteasome inhibitor |
| carfilzomib | epoxide; morpholines; tetrapeptide | antineoplastic agent; proteasome inhibitor | |
| tyropeptin a | tyropeptin A: proteasome inhibitors produced by Kitasatospora sp. MK993-dF2; structure in first source | dipeptide | |
| pr-957 | |||
| delanzomib | C-terminal boronic acid peptide; phenylpyridine; secondary alcohol; threonine derivative | antineoplastic agent; apoptosis inducer; proteasome inhibitor | |
| belactosin a | belactosin A: isolated from Streptomyces; structure in first source | ||
| oprozomib | ONX 0912: antineoplastic; an orally active proteasome inhibitor; structure in first source | ||
| ixazomib | ixazomib : A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma. ixazomib: a proteasome inhibitor with antineoplastic activity; MLN2238 is the biologically active form of MLN9708; structure in first source | benzamides; boronic acids; dichlorobenzene; glycine derivative | antineoplastic agent; apoptosis inducer; drug metabolite; orphan drug; proteasome inhibitor |
| pi-1840 | PI-1840: has both antineoplastic and proteasome inhibitory activities; structure in first source |